Jennerex, a biopharmaceutical treatment developer focused on cancer, brought in $8.3 million earlier this month from various investors, including Calvin Stiller and Korea-based Green Cross Corp. The company has raised about $18 million so far, according to VentureWire.
Headquartered in San Francisco, Jennerex plans to apply the funds over the next 18 months to advance research on a series of drug candidates, conducting testing on liver and eventually colon and lung cancer. It will pursue funding again next year to pay for a new phase of trials that could cost upwards of $30 or $40 million.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.
